Work

Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Year: 2018

Type: article

Source: Leukemia

DOI: 10.1038/s41375-018-0112-2

Authors: Mona M. Hosseini, Stephen E. Kurtz, Sherif Abdelhamed, Shawn Mahmood, Monika A. Davare, Andy Kaempf, Johannes Elferich, Jason E. McDermott, Tao Liu, Samuel H. Payne, Ujwal Shinde, Karin D. Rodland, Motomi Mori, Brian J. Druker, Jack W. Singer, Anupriya Agarwal

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, Pacific Northwest National Laboratory, Howard Hughes Medical Institute, CTI BioPharma (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Howard Hughes Medical Institute, CTI Biopharma, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: EXITO: Enhancing Cross-disciplinary Infrastructure and Training at Oregon, EXITO: Enhancing Cross-disciplinary Infrastructure and Training at Oregon, Functional Genomic Discovery of Pathway Targeted and Immune Modulatory Therapeutic Combinations in Hematologic Malignancies, Role of p27 in chronic myeloid leukemia and its potential as a therapeutic target, Assessing the power of primary drug-screens to predict clinical response., Proteogenomic Translational Research Center for Clinical Proteomic, EXITO: Enhancing Cross-disciplinary Infrastructure and Training at Oregon, Mechanisms and targeting of inflammatory cytokine-driven expansion and progression in AML, Architecture and Trajectory of Acquired Resistance to Therapy in AML

OpenAlex ID: W2794827287

FWCI: 3.764

Cites: 48

Cited by: 71

Related to: 10